J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute - MedCity NewsJohson & Johnson's attempted changes to the 340B program sparked controversy and scrutiny, emphasizing the program's role in providing drug discounts for underserved communities.
Proposition 34 explained: What California's prescription drug measure is asking youProposition 34 aims to ensure healthcare nonprofits use 98% of their 340B revenue for patient care, limiting expenditures on political campaigns.